A Meta analysis of Shensongyangxin capsule combined metoprolol in treatment of ventricular premature beats / 心血管康复医学杂志

ABSTRACT

Objective:To compare the therapeutic effects between Shensongyangxin capsule combined metoprolol and metoprolol monotherapy in treating ventricular premature beats.Methods:The related literature of Shensongyangxin capsule combined metoprolol in treatment of ventricular premature beats published from Aug 2005 to Aug 2013 were searched by computer from Cochrane Library,MEDLINE,EMbase,Wangfang Data,China National Knowledge Infrastructure (CNKI)and Chinese biomedical literature database (CBM),and were searched manually.RevMan 5.0 software was used to perform Meta analysis on data.Results:Symptomatic relief in treatment group was signifi-cantly better than that of control group [(Z=8.28,P <0.00001;OR=6.17,95%CI (4.01,9.48)];dynamic ECG improvement in treatment group was significantly better than that of control group [Z=9.37,P <0.00001;OR=3.41,95%CI (2.64,4.40)];there was no significant difference in incidence rate of adverse drug reaction be-tween two groups [Z=1.47,P =0.14;OR=0.70,95%CI (0.43,1.13)].All funnel schemas were symmetry in general,so there was small possibility of bias.Conclusion:Shensongyangxin capsule combined metoprolol possesses better therapeutic effect than metoprolol monotherapy in treating ventricular premature beats,and it doesn′t in-crease adverse drug reactions.